415
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

Brexpiprazole for the treatment of schizophrenia

Pages 109-122 | Received 14 Oct 2015, Accepted 07 Dec 2015, Published online: 20 Jan 2016

References

••The behavioral pharmacologic characteristics of Brexpiprazole are evaluated and compared with Aripiprazole and Risperidone in vivo

••The only phase 1 study for Brexpiprazole

••Study to evaluate the efficacy, safety, and tolerability of oral OPC-34712 and Aripiprazole for treatment of acute schizophrenia (STEP 203)

  • McQuade R, Hobart M, Forbes R. A phase II trial assessing the efficacy and safety of OPC-34712 in the acute treatment of adult schizophrenia (Study 331-07-203). Poster Presentation, US Psychiatric Congress; 2011 Nov 7–11; Las Vegas, NV.
  • Malla A, Sugaya K, Perry P, et al. The effect of brexpiprazole (OPC- 34712) in adult outpatients with early-episode schizophrenia: an exploratory study. Poster Presentation, American Society of Clinical Psychopharmacology Annual Meeting; 2015 Jun 22–25; Miami, FL.
  • Citrome L, Ota A, Nagamizu K, et al. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study. Poster Presentation, 70th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry, SOBP; 2015 May 18; Toronto, ON.
  • Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1):127–135.

••The published paper on BEACON trial

  • Kane J, Skuban A, Youakim J, et al. A multicenter, randomized, controlled, phase III trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Neuropsychopharmacology. 2014;39:S357–S358. Poster Presentation.
  • Duffy R, Ouyang J, Skuban A, et al. Analysis of efficacy and metabolic tolerability profile from two phase 3 studies of brexpiprazole in patients with acute schizophrenia. Schizophr Bull. 2015;41(Suppl. 1):S309. Poster Presentation.
  • Skuban A, Correll CU, Kane JM, et al. Efficacy of brexpiprazole (OPC-34712) in acute schizophrenia: results of two pooled pivotal studies. Schizophr Bull. 2015;41(Suppl. 1):S333–S334. Poster Presentation.
  • Eramo A, Skuban A, Ouyang J, et al. Incidence, onset, duration and sever- ity of akathisia with brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies. Poster presentation, American Society of Clinical Psychopharmacology Annual Meeting; 2015 Jun 22–25; Miami, FL.
  • Marder SR, Skuban A, Ouyang J, et al. Efficacy of brexpiprazole (OPC-34712) on PANSS items and Marder Factor scores: a meta- analysis of two pivotal studies in schizophrenia. Poster presentation, 168th American Psychiatric Association Annual Meeting; 2015 May 16–20, Toronto, Canada.
  • Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870–880.

••The published paper on VECTOR trial

  • Correll C, Skuban A, Youakim J, et al. Brexpiprazole for the treatment of acute schizophrenia: a randomized, controlled trial. Poster presentation, Neuropsychopharmacology, 53rd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2014 Dec 7–11; Phoenix, AZ; S474.
  • Weiss C, Skuban A, Hobart M, et al. The metabolic tolerability profile of brexpiprazole (OPC-34712) in acute schizophrenia. Poster presentation, American Society of Clinical Psychopharmacology Annual Meeting; 2015 Jun 22–25; Miami, FL; W89.
  • Correll CU, Skuban A, Ouyang J, et al. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies. Schizophr Bull. 2015;41(Suppl. 1):S307–S307. Poster Presentation.
  • Hobart M, Ouyang J, Forbes A. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Poster presentation, American Society of Clinical Psychopharmacology Annual Meeting; 2015 Jun 22–25; Miami, FL; W70.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.